How US Medical Device Companies Should Sequence Their Latin American Market Entry: A Strategic Playbook

A strategic playbook for US medical device companies with FDA clearance planning their Latin American market expansion — where to start, how to sequence, and what mistakes to avoid.

April 3, 2026

17

min read

By

Julio G. Martinez-Clark, CEO, bioaccess®

market access

medical devices

Latin America

COFEPRIS

Mexico

INVIMA

Colombia

ANVISA

Brazil

FDA

distributor

regulatory strategy

In short

Don’t start with Brazil — ANVISA registration varies by study (we confirm it per protocol). Instead, sequence Mexico and Colombia first (study-specific registration), using FDA clearance as a predicate that most LATAM regulators accept. A Tier 1 → Tier 2 → Tier 3 sequencing framework maximizes revenue velocity while managing regulatory complexity.

**Key Takeaways**

• • Don't start with Brazil — ANVISA registration is the most complex and time-consuming in LATAM (varies by study; we confirm per protocol)
• • Mexico and Colombia should come first — faster registration (varies by study; we confirm per protocol), lower complexity, strong market demand (see our INVIMA clinical trial approval process guide for Colombia)
• • FDA clearance is your biggest asset — most LATAM regulators accept it as a predicate, accelerating review (see our FDA acceptance guide for Latin American clinical data)
• • Distributors often drive international demand before regulatory clearance — plan proactively
• • Tier 1 → Tier 2 → Tier 3 sequencing maximizes revenue velocity while managing regulatory complexity

**Who Is This For?**

This guide is for US medical device company CEOs, VP Commercial/International, and regulatory leaders at companies with FDA 510(k), De Novo, or PMA clearance/approval who are considering Latin American market expansion — whether driven by distributor interest, patient demand, or strategic growth planning.

Why Do Most Device Companies Get Latin America Wrong?

For US medical device companies with FDA clearance or approval, Latin America represents a massive growth opportunity. Brazil is the world's second-largest medical device market. Mexico's healthcare system serves 130+ million people. Colombia's medical tourism industry generates billions in annual revenue. And across the region, demand for innovative medical technologies — particularly from US companies with FDA pedigree — continues to grow.

But the question startups and mid-size companies most often get wrong is sequencing — where should you go first?

The instinct is to target the biggest market: Brazil. But Brazil is also the hardest market to enter. The result: companies spend a timeline that varies by study (we confirm it per protocol) and $50,000-$100,000 on ANVISA registration before generating a single dollar of international revenue, while faster-entry markets — Mexico, Colombia, Chile — go unaddressed.

This playbook provides a framework for sequencing Latin American market entry to maximize revenue velocity while managing regulatory complexity and cost.

Why Shouldn’t You Start with Brazil?

Brazil's allure is understandable: 210+ million people, the world's second-largest medical device market (after the US), a sophisticated healthcare system with both public (SUS) and private sectors, and growing demand for innovative technologies.

But ANVISA registration is the most complex regulatory process in Latin America:

• INMETRO certification required: Brazil requires INMETRO (National Institute of Metrology) certification for medical devices, which involves factory audits, quality system assessment, and product testing — a process that can take 6-12 months independently
• Local representation mandatory: Companies must establish a Brazilian legal entity or appoint an authorized local representative (Registrant) — adding cost and administrative complexity
• ANVISA review timelines: varies by study; we confirm per protocol for Class III/IV devices, with potential technical questions that can extend the timeline further
• Portuguese documentation: All technical documentation must be submitted in Portuguese — requiring professional translation of entire technical files
• Post-market requirements: Brazil has extensive post-market surveillance requirements, including periodic safety update reports and adverse event reporting through ANVISA's NOTIVISA system

**The Brazil Trap**

Companies that start with Brazil often find themselves a timeline that varies by study (we confirm it per protocol) into the registration process with no revenue, mounting regulatory costs, and board/investor pressure to show international traction. Meanwhile, they've missed a timeline that varies by study (we confirm it per protocol) of potential revenue in faster-entry markets like Mexico and Colombia — markets where their FDA clearance provides a significant competitive advantage.

Why Should Mexico and Colombia Come First?

Mexico (COFEPRIS): Faster, FDA-Friendly

Mexico offers the fastest large-market entry point in Latin America for FDA-cleared devices:

• COFEPRIS registration timeline: varies by study; we confirm per protocol for devices with existing FDA clearance
• FDA clearance accepted as predicate: COFEPRIS recognizes FDA 510(k) and PMA as reference, streamlining technical review
• Massive market demand: 130+ million population, large private hospital network, growing cross-border medical tourism from US patients
• Geographic proximity: Shared border with the US, same/similar time zones, established logistics infrastructure
• Growing chiropractic, physical therapy, and surgical specialty markets driving demand for US devices
• Existing distributor networks: Multiple established medical device distributors with US relationships

Colombia (INVIMA): Strong Distributor Networks

Colombia provides an excellent second-market entry point:

• INVIMA registration timeline: varies by study; we confirm per protocol for FDA-cleared devices
• US-trained physician base: Many Colombian specialists trained at US medical centers, creating natural demand for US devices
• Growing medical tourism: Medellín and Bogotá are major medical tourism destinations, with international patients seeking access to advanced technologies
• Strong distributor networks: Well-established distribution infrastructure with companies experienced in medical device commercialization
• Competitive pricing environment: Colombia's healthcare market supports premium pricing for innovative devices with demonstrated clinical evidence

How Does the Distributor-Led Expansion Model Work?

One of the most common patterns bioaccess® observes in Latin American market entry is the distributor-led demand signal. Here's how it typically works:

• A US physician with international recognition uses your device at a US medical center
• International physicians who trained at the same center (or attend the same conferences) learn about the device
• Those physicians — now practicing in Colombia, Mexico, or Brazil — want to use the device for their patients
• A local distributor contacts you, saying they have 'interested doctors' and want to distribute your device
• The distributor may even attempt to import devices before regulatory clearance is in place — creating compliance risk

This pattern creates both an opportunity and a risk. The opportunity: there's genuine market demand for your device, driven by physician familiarity rather than marketing spend. The risk: if you don't proactively manage the regulatory pathway, distributors may import devices informally — exposing your company to regulatory liability and potentially damaging your reputation with the local regulatory authority.

**The Right Response to Distributor Interest**

When a distributor contacts you about Latin American distribution, the correct response is NOT to immediately sign a distribution agreement. Instead: (1) validate the market demand independently, (2) initiate regulatory registration in the target country, (3) negotiate distribution terms contingent on regulatory clearance, and (4) ensure the distributor has legitimate regulatory compliance infrastructure — not just sales relationships.

How Can You Leverage ISO 13485 and FDA Clearance?

Companies with ISO 13485 certification and FDA 510(k) clearance have a significant competitive advantage in Latin American markets. Here's how to maximize that advantage:

• Most LATAM regulators accept FDA clearance as a predicate: This significantly reduces the technical documentation burden and accelerates review timelines
• ISO 13485 certification satisfies QMS requirements: Many LATAM regulatory frameworks require evidence of quality management — ISO 13485 certification satisfies this requirement
• Clinical evidence from FDA submission transfers: Clinical data generated for your FDA submission can be referenced in LATAM registration dossiers
• EU MDR path can run in parallel: If you're also pursuing EU MDR (CE marking), some documentation (e.g., clinical evaluation reports) can serve both EU and LATAM submissions
• Prioritize when resources are limited: If you can only pursue one international pathway at a time, LATAM registration is faster and less expensive than EU MDR — start there

What Is the Personal Use Exclusion?

International demand for medical devices often starts through informal channels before formal regulatory clearance is obtained:

Personal use exclusions: Patients traveling to the US for treatment with a specific device, then returning to their home country. This occurs frequently in orthopedics, ophthalmology, and aesthetics — patients from Mexico, Colombia, and Brazil fly to US medical centers for specific procedures.

Conference exposure: International physicians attending US medical conferences (TCT, AAOS, AAO) see new devices, watch live cases, and want to adopt the technology at their home institutions.

Physician training: International surgeons completing fellowship or training at US medical centers learn to use specific devices, then seek access when they return home.

**Market Signal → Regulatory Action**

These "gentle seeding" patterns are market signals that should trigger proactive regulatory strategy — not passive observation. When you see international physicians expressing interest, patients traveling for your device, or distributors making inquiries, it's time to initiate formal registration in those markets. The cost of registration ($10K-$40K per country) is trivial compared to the revenue opportunity, and proactive registration positions you ahead of competitors who are waiting for "sufficient demand."

What Is the Practical Sequencing Framework?

Based on bioaccess®'s experience helping device companies enter Latin American markets, here is a practical sequencing framework:

Tier 1 — Fast Entry (Months 1-9):

Tier 2 — Medium Complexity (Months 6-18, start after Tier 1):

Tier 3 — Strategic but Complex (Months 12-30, parallel with Tier 2):

This tiered approach means you're generating international revenue from Mexico and Colombia on a timeline that varies by study (we confirm it per protocol), expanding to Chile/Peru/Argentina in months 12-18, and entering Brazil — with its longer regulatory timeline — as a strategic play rather than a first-mover bet.

Frequently Asked Questions

JM

Julio G. Martinez-Clark

CEO & Founder, bioaccess® · 15+ years leading medical device market access across Latin America · Has managed 100+ device registrations across COFEPRIS, INVIMA, ANVISA, ISP, DIGEMID, and ANMAT · Direct experience with the distributor-led expansion model for US device companies.

Full bio

LinkedIn

Ready to Plan Your LATAM Market Entry?

bioaccess® provides end-to-end medical device registration and market access services across 10+ Latin American countries. Whether you're responding to distributor interest, planning proactive international expansion, or managing an existing LATAM portfolio, our team can provide country-specific regulatory assessments, registration timelines, and commercialization strategy.

Schedule a Strategy Call

Estimate Your FIH Budget

Related resources:

• Market Access Services — /market-access
• Device Registration Pricing — /market-access
• Clinical Trials in Mexico — /clinical-trials-mexico
• Clinical Trials in Colombia — /clinical-trials-colombia
• Clinical Trials in Brazil — /clinical-trials-brazil
• Early Feasibility Studies — /early-feasibility-studies